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■ Abstract Background The valid-
ity of clinical guidelines changes
over time, because new evidence-
based knowledge and experience
develop. Objective Hence, the Euro-
pean clinical guidelines on hyper-
kinetic disorder from 1998 had to
be evaluated and modified. Method
Discussions at the European Net-
work for Hyperkinetic Disorders
(EUNETHYDIS) and iterative cri-
tique of each clinical analysis.
Guided by evidence-based infor-
mation and based on evaluation
(rather than metaanalysis) of the
scientific evidence a group of child
psychiatrists and psychologists
from several European countries
updated the guidelines of 1998.
When reliable information is lack-
ing the group gives a clinical con-
sensus when it could be found
among themselves. Results The
group presents here a set of recom-
mendations for the conceptualisa-
tion and management of hyperki-
netic disorder and attention
deficit/hyperactivity disorder
(ADHD). Conclusion A general
scheme for practice in Europe
could be provided, on behalf of the
European Society for Child and
Adolescent Psychiatry (ESCAP).
■ Key words ADHD – HKS –
guidelines – European – children
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Introduction
Hyperkinetic disorder is a persistent and severe impair-
ment of psychological development resulting from a
high level of inattentive, restless and impulsive behav-
iour. Its onset is in early childhood: by definition before
the age of 7, nearly always before the age of 5 and fre-
quently before the age of 2 years. It often persists into
adolescence and adult life, and puts sufferers at risk for
a range of abnormalities in personality development.
The adverse outcomes include delinquency and other
antisocial behaviour and underachievement in school.
Longitudinal studies indicate that the inattentive and
restless behaviour is a developmental risk. It is not just a
marker to some more fundamental kind of disadvan-
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tage. The treatment of severely hyperactive behaviour is
therefore a major target for child mental health services.
The importance of treating hyperactivity is estab-
lished.It has been hard to establish European guidelines,
because a variety of different clinical traditions have
evolved within Europe [143], and there has been wide-
spread public controversy about the disorder and possi-
ble over-prescription in the United States. In 1998 an ap-
proach to European guidelines was produced by a group
of experts, including some of the present authors [169].
Since then, however, a good deal has changed. Profes-
sional consensus has emerged in most countries, re-
flected in published national protocols [25, 33, 70]. The
use of treatments for hyperactivity and attention deficits
has increased markedly, especially for stimulant med-
ication [22, 139]. Scientific knowledge has increased
rapidly [134]. There is therefore a need for revision and
update of these “European guidelines” and we have
aimed at achieving this on behalf of ESCAP (European
Society for Child and Adolescent Psychiatry). The revi-
sion has been greatly helped by discussions at the Euro-
pean Network for Hyperkinetic Disorders (EUNETHY-
DIS). Practice does, of course, vary between countries
and centres; and these guidelines are therefore intended
as a statement of evidence-based or consensus-driven
general principles rather than detailed protocols for
clinical management. The development of specific pro-
tocols will need to take place at the local level, involving
other stakeholders such as users and purchasers of ser-
vice; we hope that these guidelines will form a useful
framework.
Influences on pathogenesis
The exact aetiological pathways of AD/HD are un-
known. AD/HD aggregates within families with a 3–5
times increased risk in first-degree relatives [45]. Twin
studies have found considerable heritability with ge-
netic factors contributing 65 % to 90 % of the phenotypic
variance in the population [173]. High heritability must
not be confused with genetic determinism and some
caution should be adopted in counselling families about
causes.
Molecular genetic studies have found associations
with variations in genes for the dopamine receptors 4
(DRD4 7-repeat allele) and 5 (DRD5 148bp-allele), and
the dopamine transporter (DAT1 10-repeat allele) [30,
46, 94]. While the 10-repeat allele of DAT1 has been as-
sociated with an increased expression of the transporter
[49, 99], the 7-repeat allele of DRD4 seems to encode a
receptor that is subsensitive to dopamine [5].
Preliminary evidence suggests aetiological influ-
ences of the receptor genes DRD1 [101] and 5-HT(1B)
[66, 118], the Taq 1 polymorphism of the dopamine beta
hydroxylase gene [31,148],and the SNAP-25 gene,which
is involved in the regulation of neurotransmitter release
[12, 100].
Each of these risk alleles increases the relative risk for
AD/HD only slightly (odds ratios: 1.2–1.9), consistent
with the hypothesis that, in most cases,AD/HD is a com-
plex disorder influenced by the interaction of multiple
aetiological factors, each of minor effect. However, some
rarer genes, including fragile X and resistance to thyroid
hormone, may show large effects. Some genes involved
may have pleiotropic effects. Thus, it has been suggested
that AD/HD and reading disability [6, 147, 185], and
AD/HD and autism [6, 147] share genetic susceptibility
factors.
There are also associations with a variety of environ-
mental risks, including prenatal and perinatal obstetric
complications, low birth weight, prenatal exposure to
benzodiazepines, alcohol, or nicotine, and brain dis-
eases and injuries [24, 51, 97, 98, 166, 171]. Severe early
deprivation, institutional rearing, idiosyncratic reac-
tions to food,and exposure to toxic levels of lead are also
considered to have aetiological importance [17, 127, 130,
170]. The quality of relationships within the family and
at school can be considered as maintaining or protective
factors [17, 130]. Gene-environment interactions seem
likely (e. g. DAT-10 allele multiplies the risk of maternal
prenatal smoking [77]), but have not yet been studied
extensively.
Studies using structural and functional brain imag-
ing, electrophysiology and transcranial magnetic stim-
ulation have shown various abnormalities in frontal,
temporal, and parietal cortical regions, basal ganglia
(striatum), callosal areas, and cerebellum [13, 14, 23, 28,
29, 47, 102, 111, 126, 157, 163, 176, 190]. The morpholog-
ical abnormalities seem to be evident early, non-pro-
gressive, and not a result of stimulant treatment [29].
Converging evidence from a variety of sources sug-
gest that catecholaminergic dysregulations are centrally
involved. The molecular genetic findings above, the ef-
fectiveness of stimulants and noradrenergic substances
[4], some animal models [e. g., 128, 138], and functional
imaging studies – which suggest altered DOPA decar-
boxylase activity in the striatum and prefrontal areas [42,
43], as well as increased striatal dopamine transporter
binding capacity [37, 84] – are all in keeping with this.
Neuropsychological and electrophysiological studies
have found various alterations in higher-order cognitive
functions [9,114,142],motivational processes [129],and
more basic information processing stages [13, 83, 135,
149, 174, 188]. The tests used are summarised in the Ap-
pendix.
Some research evidence suggests heterogeneity at
several levels: phenotypic [e. g., 16], neuropsychological
[e. g., 150], psychophysiological [e. g., 7, 23, 125], and ge-
netic [e. g., 107, 175, 186]. There may be multiple devel-
opmental pathways from aetiological factors to behav-
ioural symptoms [151, 152].
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Prevalence
Several studies converge on a point prevalence for hy-
perkinetic disorder of about 1.5 % in the primary school
age population – which is the age at which the problem
is most likely to be referred for specialist attention [163].
In the UK,the rates are similar in studies stemming from
the 1970s and 1990s – a period during which the recog-
nition of the disorder changed greatly. The administra-
tive prevalence – the rate at which the disorders are in
practice recognised – varies vary greatly between diffe-
rent European countries, from approximately zero to
nearly 2.5 % [81].Attention deficit without hyperactivity
has received less research attention, but is troublesome
for something like another 1 % of the school age popu-
lation [166].
The prevalence of the broader category of AD/HD is,
obviously, higher. The estimates vary from about 4 % to
19 % but the usual figures adopted are those of the DSM
IV estimates of 3–5 % [26]. The exact figures found in
studies probably depend more upon the cut-off that is
chosen than on any major differences between popula-
tions [163].Hyperactive behaviour is distributed contin-
uously in the population, and the exact cut-off taken is
somewhat arbitrary. In some populations – for instance,
the Chinese population in Hong Kong – careful diagnos-
tic measures have suggested that there may be a lower
prevalence of disorder than in Europe [88].Interestingly,
however, the apparent prevalence taken from rating
scales was higher in Hong Kong than in Western popula-
tions – perhaps illustrating the extent to which the disor-
der is socially defined and influenced by the concern that
adults feel for these behaviours in different cultural set-
tings.Methodological differences,however,usually make
it hard to compare rates between countries.
Diagnosis
The diagnosis of hyperkinetic disorders follows the
ICD-10 criteria.
The DSM-IV category of AD/HD is more broadly de-
fined and is a commoner diagnosis. In both schemes, the
behaviours to be recognised are very much the same.
The differences come in the ways that the symptoms are
weighted and combined into categories:
The ICD-10 diagnosis of hyperkinetic disorder is the
narrower category, and it appears that nearly all cases of
hyperkinetic disorder should be included within
AD/HD. The additional criteria of ICD-10 are that all
three problems of attention, hyperactivity and impul-
siveness should be present; that more stringent criteria
for pervasiveness across situations are met; and that the
presence of another disorder such as anxiety state is in
itself an exclusion criterion – the expectation is that
most cases will have a single diagnosis.
Both these diagnostic schemes have their advantages
and disadvantages and a narrower or a broader defini-
tion will be suitable for different purposes. Many Euro-
pean clinicians prefer to use the wider definition of
AD/HD. We see no contradictions involved. Indeed, it is
helpful to use both concepts. In the assessment of an in-
dividual child, the first question then becomes whether
the criteria for AD/HD are met, i. e. whether there is any
target problem for investigation and management. If
there is, then one should proceed to a finer grain of clas-
sification. Does the child also meet the criteria for hy-
perkinetic disorder; or, if they fall only into the wider de-
finition, is it possible to assign an alternative type of
psychopathology?
Impairment
Diagnosis requires that there should be clear evidence of
clinically significant impairment in social, academic, or
occupational functioning. This requirement is essential
not only for AD/HD but for all mental disorders, in or-
der to differentiate disorders from ubiquitous symp-
toms and variations of behaviour. Impairment implies
not only a higher severity or frequency of symptoms but
also interference with functioning in the major life do-
mains of the child, e. g. at home, at school, with friends
or elsewhere.
A valid instrument for the assessment of impairment
is the Children’s Global Assessment Scale (CGAS) by
Shaffer et al. [144]. The CGAS runs from 0 to 100 with 0
indicating a child with the most severe disorder and im-
pairment and 100 the most healthy and well functioning
child. Cut-offs have been proposed in order to differen-
tiate normal functioning from severe problems in need
of treatment [144, 161]. The multiaxial classification of
child and adolescent psychiatric disorders by the WHO
has introduced a similar scale to measure the level of
psychosocial functioning [187]. Axis six of the multiax-
ial scheme (MAS) runs from 0 indicating superior/good
social functioning to 8 reflecting gross and pervasive so-
cial disability. Both CGAS and Axis six of the MAS are
suitable for the clinical assessment of psychosocial im-
pairment resulting from mental disorders in children
and adolescents.
The CGAS has also been influential for the definition
of AD/HD according to DSM-IV.A cut-off point of 60 on
the CGAS – indicating a level of clinical impairment that
requires treatment – has been used in order to define the
number of symptom criteria for AD/HD. In a field trial
it was found that 5 symptoms of AD/HD had to be pres-
ent in order to arrive at the CGAS cut-off point of 60
[85]. In order to be conservative and avoid false-posi-
tives the numbers were increased by one to 6 (or more)
symptoms of inattention and hyperactivity-impulsivity.
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Comorbidity
The co-existence of other types of psychopathology is
very common. The reasons appear to be different in dif-
ferent forms [54].
■ Conduct disorder
Oppositional defiant and conduct disorders are very
common in hyperactivity, and genetic influences over-
lap. They should often be seen, not necessarily as a dif-
ferential diagnosis or a comorbid condition, but as a
complication. Longitudinal studies indicate that in pri-
mary school-aged children hyperactive behaviour is a
risk factor for conduct disorder, that it appears over time
even in children who showed a pure pattern of hyperac-
tivity without conduct disorder at the beginning of their
problems, and that conduct disorder does not give rise
to hyperactivity in the same way [164].
■ Emotional disorders
Much less is known about the reasons for the frequent
coexistence of hyperactivity and problems of anxiety
and depression. Some children may develop low self es-
teem and insecurity as a result of failures at school and
interpersonal relationships
■ Specific learning disorders
Children with hyperkinetic disorders are more likely to
show neurodevelopmental delays of various types. Lan-
guage milestones are achieved later than normal, ex-
pressive language is unduly simple, sensory motor coor-
dination is often impaired, handwriting is poor, and
reading ability is behind that expected for chronological
age [166].
McGee and Share [91] suggest that children with on-
set of hyperactivity after school entry are more likely to
have behaviour problems confined to school, and to
show specific learning difficulties. The suggestion is
therefore that some children may enter school with their
cognitive function compromised by neuropsychological
deviations. The attendant stress in adjusting to class-
room demands leads to disturbances in the control of
activity and attention. For other children, a primary dis-
turbance of attention and impulse may give rise to sec-
ondary academic problems, either through inability to
cope with the work or aversion to it.
■ Pervasive developmental disorders
Children with autism often show hyperactive behaviour,
and autistic symptoms are sometimes seen in the hy-
peractive. Research is now on its way to clarify the rela-
tionship between them. Clinically, children with hyper-
kinetic disorder and an autistic type of social
impairment will sometimes show a partial response to
stimulants (though caution is needed in view of possible
adverse effects). It is therefore desirable to recognise
both disorders when they are present. The ICD-10 (but
not the DSM) scheme includes a diagnosis of “Hyperki-
nesis with stereotypies”. This is in our experience usu-
ally accompanied by social impairment and best seen as
a part of the autism spectrum.
■ Tic disorders
A number of children with AD/HD develop comorbid tic
disorders during their early school years [124]. In these
cases, the degree of psychosocial impairment is usually
determined by AD/HD and it may be the target for ther-
apy.
■ Developmental coordination disorder
AD/HD is often accompanied by problems in sensory
motor coordination, especially seen as poor handwrit-
ing,clumsiness,poor performance in sports and marked
delays in achieving motor milestones [53, 76]. If signifi-
cant interference with academic achievements or activ-
ities of daily living is observed, treatment with stimu-
lants seems to be indicated: it may improve motor
coordination and increase the motivation of the child
for further sensorimotor training.
■ Bipolar disorder
The main DSM-IV inclusion criteria for mania are elated
mood and/or grandiosity. There is still some contro-
versy about the existence and definition of preadoles-
cent mania [65, 67, 79]. More work is needed on the phe-
nomenology and diagnosis of mania in children, on its
natural history and on its familial correlates. Neverthe-
less, some studies which describe high rates of overlap
between AD/HD and mania exist. This might have im-
plications for treatment approaches in such cases, but
consensus is not reached yet.
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■ Substance abuse
The relationship between AD/HD and Substance Misuse
Disorders is complex and relatively understudied. Ele-
vated rates of AD/HD are reported among those seeking
treatment for opiate, cocaine and other substance use
disorders. Those with AD/HD were younger at presenta-
tion and reported earlier onset of drug abuse, more fre-
quent and intense drug use, higher rates of alcoholism
and higher rates of previous treatment [90]. These stud-
ies however all have the problem of retrospective re-
porting of AD/HD symptoms by adults with current
substance misuse problems. Prospective studies of re-
ferred and non-referred children with AD/HD followed
up into adolescence and early adulthood also report in-
creased rates of drug use and abuse, including smoking,
in AD/HD groups [71]. It is not surprising that this as-
sociation is much stronger in samples followed up into
early adulthood than in those only followed up into ado-
lescence as those in the younger age range are not fully
through the peak age of substance misuse risk (e. g. 19 to
22 years). Whilst controlling for comorbid disorders
(particularly conduct disorder) substantially weakens,
and in some samples completely accounts for this asso-
ciation [90], there is some evidence that non-comorbid
AD/HD in adults does act as an independent risk factor
for substance misuse [183].
Differential diagnosis
The separation of autism spectrum from hyperactivity
is not based on excluding hyperactive features but on de-
tecting the presence of autistic types of impairment.
Anxiety and mood disorders are sometimes the
cause of hyperactive behaviour, because they make chil-
dren agitated and preoccupied. They are best assessed
by the combination of psychiatric interview with the
child and a careful history of emotional symptoms.
Acute adjustment disorders can readily be distinguished
by their time course, even when activity and attention
changes are seen. Attachment disorders should also be
considered in the differential. Some children who have
had massive and prolonged disruption of attachment re-
lationships in early childhood show a rather character-
istic course in which an initial period of indiscriminate
clinging to adults is followed, during school years, by a
pattern of inappropriately outgoing and inattentive ac-
tivity, with an unreserved contact with strangers and of-
ten a lack of deep and trusting relationships.
Chronic brain syndromes may present with hyperac-
tive behaviour, as with other psychiatric syndromes:
brain dysfunction is therefore not a differential diagno-
sis, but a possible cause. Mental retardation can coexist
with hyperkinetic disorders, and does not exclude the
diagnosis. The clinician needs to judge whether the dis-
turbance of activity and attention is too severe to be ac-
counted for by the known developmental level of the
child.
Conduct disorders without any attention deficit may
sometimes give difficulty in the differential. This comes
especially because uncontrolled behaviour is the norm
in oppositional defiant disorders. It may be difficult to
tell – especially in a younger child – whether an appar-
ently inattentive pattern of failing to do activities is in
fact due to defying adult expectations to conform.It may
be necessary to follow children over some time, until the
pattern is clarified. It is often not until school entry
places demands upon attention that it is possible to be
clear whether there is an impairment. During that pe-
riod the clinician should be aware of the possibility of
misdiagnosis both ways.
Work-up
At the level of primary care, the first responsibility is to
detect the symptoms of AD/HD. Parental checklists, and
accounts from teachers, are valuable in order to make
sure that these are indeed the presenting problems
rather than the commoner difficulties of sleep or con-
duct disturbance. Physical examination should be done
to make sure that there is no evident underlying physi-
cal illness, hearing should be checked, and any history of
epilepsy sought. If the symptoms of AD/HD are causing
social impairment, then the next step should be referral
to a community child mental health service, or if this is
not available to developmental paediatrics. Even in the
private sector, a multidisciplinary approach is to be pre-
ferred.
At the level of secondary care, responsive advice
should always be provided. If the problem does not re-
solve, then a comprehensive diagnostic assessment
should be undertaken. Assessment should comprise
clinical interview with the parents, and separately with
the child; obtaining kindergarten, preschool or school
information; testing intelligence, achievement, attention
and impulsivity as indicated; making behavioural ob-
servations during clinical examinations and testing; and
physical evaluation. The child must be seen on more
than one occasion; AD/HD symptoms must be evaluated
carefully against what is expected at that developmental
level; the assessment needs to be full enough to find any
alternative explanation of the symptoms that may be
present, and any significant comorbidity. It is unlikely
that a single-handed doctor will be able to provide such
a depth of assessment without multidisciplinary input.
Nevertheless stimulants should only be prescribed after
a full assessment has been made.
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■ Clinical interview with the parent(s)
General evaluation should clarify presenting com-
plaints, make a systematic evaluation of psychopatho-
logical symptoms, and describe how problems devel-
oped. The developmental history is important and
should include previous professional reports. One needs
to reach an adequate account of affected family mem-
bers (relevant to a genetic aetiology), pregnancy and
birth history (foetal growth, toxaemia, bleeding or se-
vere infections in pregnancy, maternal diabetes or
epilepsy, other maternal illnesses or traumas, poor nu-
tritional state of the mother, use of medication, nicotine,
alcohol or drugs, gestational age, birth complications,
birth weight, neonatal complications), early develop-
mental history (milestones for psychomotor develop-
ment, language, attachment, sleep and feeding prob-
lems, growth, and early temperament); medical history,
especially tics and epilepsy; medication (especially
anticonvulsants, antihistamines, sympathomimetics,
steroids) and (if adolescent) history of psychosis.
The assessment also needs to be sufficiently detailed
to address family functioning and family problems (e. g.
financial problems, problems of other family members,
parental conflicts), coping styles of the parents, ex-
pressed warmth and hostility, social network and other
resources.
Specific questioning should include the behaviours
that comprise the ICD-10 and DSM-IV diagnoses, any
situational variation in them, their times of onset and
development, and their presence in other family mem-
bers – together with that of related problems (such as
behavioural and learning problems, emotional prob-
lems, tics, conduct disorder, and alcoholism). Symptoms
of comorbid and differential diagnoses should be asked
about (see above; in adolescents one should also con-
sider borderline personality disorder, substance abuse,
and schizophrenic disorders).
Parent rating scales are useful as a supplement to the
interviews, not a replacement. They have the advantage
of systematic cover but the disadvantage of uncertainty
about how the parents make the ratings. Halo and adap-
tation effects are to be expected. See Appendix 1.
■ Interview with the child
The child’s self-report is helpful, especially if the child is
6 or older, but more for general adjustment and comor-
bidity than for the presence or absence of diagnostic
symptoms. It should therefore be focussed on function-
ing in the family, the school and the peer group; general
evaluation of psychopathology (especially emotional
problems and self-esteem); and the children’s attitudes
to and coping with their disorder. Self-report rating
scales may be useful, as a supplement to the interview,
especially for detecting emotional problems in children
of 9 years or more.
Behavioural observation during clinical examina-
tions and testing is very useful when problems are
shown. Hyperkinetic symptoms, however, may not be
present in a novel and arousing setting, so repeated as-
sessment is often needed. The examiner should also as-
sess social disinhibition, the ability to concentrate and
persist, and any evidence of language disorder. Class-
room observation (for instance, by an educational psy-
chologist) is very helpful but not always feasible.
■ Kindergarten, preschool or school information
If parents agree, it is essential to obtain information
from the teacher (or nurse or other caregiver) about be-
haviour and behaviour problems, developmental and
social functioning, situational variation in behaviour,
and symptoms indicating comorbid or differential diag-
noses. Standardised questionnaires are a good way of
obtaining systematic coverage. See the Appendix for
available scales; it helps to use both broad band rating
scales and rating scales specifically developed to assess
AD/HD symptoms. Written or telephoned reports are
also needed, both for a full view of the child at school,
and to assess the coping style of the teacher and the
teacher-child relationship.
■ Psychometric tests
Currently, there are no psychological tests, which are di-
agnostic of AD/HD. Hence, we provide here some prin-
ciples by which psychological assessment might be un-
dertaken. There are a wide variety of tests, which are
useful in the assessment of children with AD/HD. In the
appendix we include a list of tests and key references
from which each country can search for normative
equivalent tests.
Standards by which tests should be evaluated include
validity, reliability, age/sex norms and, preferably, paral-
lel versions. Important for clinical work is the differen-
tial diagnostic validity of tests. Assessment of IQ is
useful to determine academic performance versus
academic potential. From a neuropsychological point 
of view, tests whose specific brain activation areas are
already known (e. g. from fMRI and other neural imag-
ing research studies) have clear advantages in testing,
when appropriate control tests are also carefully chosen.
A further consideration is follow-up of patients. A test
that has norms has an advantage for comparing chil-
dren with their peers. However, if the intention is to
measure stability, decline or improvement with long-
term follow-up (i. e. within subject comparison), careful
inspection of the test-retest reliability and the standard
E. Taylor et al. I/13
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error of the test is required, before conclusions can be
drawn.
Lack of resources often means that priorities have to
be set; but testing should always be considered when
there is any problem related to classroom adjustment or
progress. When time is scarce, a short WISC or equiva-
lent is better than no assessment. Speech and language
tests are needed when there is evidence of difficulty in
communication. Tests of attention and impulsivity have
developed markedly in recent years. They are still essen-
tially research tools, and have not been standardised for
individual diagnosis, but they can give clues to the na-
ture of the problem in an individual case (see Appen-
dix).
■ Physical evaluation
Height, weight, and head circumference should always
be recorded.A general examination is always needed, in-
cluding assessment of physical health and any evidence
of breakdown of care, and any stigmata of congenital
disorder (e. g. foetal alcohol syndrome, Williams syn-
drome, neurofibromatosis). There should be a check on
vision (Snellen chart) and hearing (clinical screen and
audiogram if indicated). The examination should look
particularly for any evidence of neurodevelopmental
immaturity in gross and fine motor functions and for
motor and vocal tics.
Investigations should not be routine but guided by
history and physical examination. If there is a history
suggestive of seizures, an EEG should be carried out. If
there is a developmental delay, then chromosome esti-
mation and a DNA assessment of the Fragile X gene
should be done (further gene assessments may be rec-
ommended in the near future, but at present the clinical
significance of variant alleles is not clear). Audiograms
are needed when a clinical evaluation has not ruled out
significant hearing loss. Brain scanning and neuropsy-
chological tests are not necessary unless there is partic-
ular reason to suspect a structural brain lesion. Func-
tional imagining remains at present a research
technique.
Treatment
Psychological interventions, educational change, med-
ication and diet are all used for children with hyperki-
netic disorders. They should all be available, and their
use should be guided by a treatment plan drawn up for
the individual. Most hyperactive children have many
problems, and multimodal intervention is usually indi-
cated.
■ Psychoeducational measures
Education and advice should be the base of any treat-
ment. One should interview parents, child and – ideally
– the teacher or nurse, about their health beliefs and
causal and control attributions; and inform them all
about hyperkinetic disorders – especially symptoms,
aetiology, clinical course, prognosis and treatment.
Consultation with parents and school, on appropriate
class or school placement and management, is nearly
always needed. Children who are old enough should 
be educated about self-observation and self-manage-
ment.
The therapist should also help parents and teachers
to identify specific problem situations and find behav-
iour management techniques for them. The most widely
relevant techniques are paying positive attention to ap-
propriate behaviour and compliance, giving commands
more effectively, and using appropriate negative conse-
quences for problem behaviours.
■ Parent training and behavioural interventions 
in the family
Parent training and behavioural interventions in the
family have been shown to be effective by random allo-
cation trials [112]. There are many approaches, and the
following suggestions are made, not to be prescriptive,
but to provide a brief framework that commands wide
clinical consensus [10, 35].
 Identify specific problem situations, and specific be-
haviour problems within them, and the immediate
precipitants of disruptive behaviour. Monitor the
child’s progress continuously.
 Analyse positive and negative consequences and con-
tingencies of appropriate and problem behaviours
together with the parents. Marked inconsistency in
applying negative consequences to problem behav-
iour, and positive consequences to appropriate be-
haviours should be identified if it is present.
 If coercive and unpleasant parent-child interactions
occur very often, while positive parent-child interac-
tions rarely occur, enhance parental attending skills
during supervised playtime sessions.
 Teach the parents effective methods of communicat-
ing commands and setting rules (e. g. making eye
contact with the child; not giving too many com-
mands at once; framing commands positively) and of
paying positive attention to child compliance. Use
specific problem situations (e. g. mealtimes) in order
to train these skills.
 Use token systems in order to reinforce appropriate
behaviour in specific situations. In general, preferred
activities (e. g. leisure activity together with parents,
special playtime together with parents) should be
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used as backup-reinforcers – rather than material re-
wards such as candy.
 Develop together with the parents appropriate nega-
tive consequences for problem behaviour. These con-
sequences should be closely and consistently linked
to the problem behaviour.
 Use response cost systems in order to reduce very fre-
quent problem behaviours (e. g. often leaves seat dur-
ing mealtime or homework; frequent non-compliant
behaviour to different family rules). Teach the par-
ents to remove chips or points from a pool if the
problem behaviour occurs. The remaining chips be-
long to the child and can be changed into backup re-
inforcers.
 Use time-out from reinforcement as a punishment
procedure for more serious forms of child non-com-
pliance if negative consequences to problem behav-
iour are not effective. This intervention has to be ex-
plained very carefully to the parents and has to be
monitored very carefully lest it become punitive.
 Integrate the child as an active member in this thera-
peutic process as far as possible. Use self-manage-
ment procedures in school-aged children in order to
enhance the interventions. Teach self monitoring of
problem behaviours in specific situations (e. g. leav-
ing seat during homework). Teach the children to
evaluate their own behaviour and to reinforce them-
selves.
 In adolescence, use contingency contracting rather
than token systems or response cost systems and
stress self-management procedures. Use problem-
solving and communication training as well as cog-
nitive restructuring to reduce parent-adolescent con-
flicts.
■ Behavioural interventions in the kindergarten, 
the preschool or the school
Behavioural interventions in the kindergarten, the
preschool or the school are known to be effective in re-
ducing hyperactive behaviour and promoting social ad-
justment [38]. No one scheme has been shown to be su-
perior to others, and the following outline is an
integration of several [10, 40, 35].
 Discuss classroom structure and task demands (e. g.
having the child seated close to the teacher, brief aca-
demic assignments, interspersing classroom lectures
with brief periods of physical exercise).
 Identify specific problem situations and specific be-
haviour problems (e. g. blurts out answers before
questions have been completed; leaves seat in class-
room). Monitor the child’s progress frequently with a
rating scale.
 Analyse positive and negative consequences and con-
tingencies of appropriate and problem behaviours.
 If coercive and unpleasant teacher-child interactions
occur very often while positive teacher-child interac-
tions rarely occur, then it may be possible to enhance
the differential attending skills of the teacher – for ex-
ample, during individual feedback after a period of
observation. In any event, teachers often appreciate
discussion of effective methods of communicating
positive commands, setting rules, paying positive at-
tention to child compliance, and developing appro-
priate negative consequences to problem behaviours.
 Use token systems in order to reinforce appropriate
behaviour in specific situations. Back-up reinforce-
ment may be located in the kindergarten or school
(e. g. special playtime or lesser homework assign-
ment), at home, or outside (e. g. special playtime with
a therapist).
 Response cost systems are useful to reduce very fre-
quent problem behaviours (e. g. often leaves seat, or
disrupts others).
 Use brief time-out from reinforcement as a punish-
ment procedure for more serious forms of child non-
compliance if negative consequences to problem be-
haviour are not effective. Make sure, however, that
leaving the classroom is not positively reinforcing to
the child and that it does not become punitive.
 As considered above, the child needs to be integrated
as an active member in this therapeutic process.
■ Cognitive behaviour therapy of the child
Summer treatment programmes with social skills train-
ing and contingency management have been proven to
be effective [113]. Isolated self-instructional approaches
have not been shown to be effective by controlled trial
[1] but experience suggests they may be helpful in indi-
viduals in combination with other behavioural ap-
proaches. Treatment generalisation is often limited, all
the more if the application of the newly acquired skills
is not reinforced in the natural environment of the child.
They should be used only if the child is able to apply self
instruction – in practice from the age of 7 years or
greater. Self-instruction is most relevant if the child is
motivated and if impairing symptoms of inattention or
impulsivity can be observed even under optimal learn-
ing conditions, e. g. with reinforcement for attentive and
reflective behaviour.
 Teach the child steps of self instruction (“Stop, what
is the problem? – Are there possible plans? – What is
the best plan? – Do the plan! – Did the plan work?”).
 Train self instruction on different materials thus en-
hancing internalisation of the steps.
 Apply self-instruction procedures to social problem
solving if deficits in social problem solving are pres-
ent.
 Enhance training generalisation by using self moni-
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toring and self evaluation of whether procedures
have been followed. Teach parents and teachers to
help the child to apply self-instruction procedures at
home or at school.
Cognitive behaviour therapy (CBT) is essentially a form
of self-instructional training, though the term CBT 
is sometimes used loosely to cover most of the psycho-
logical interventions described here. Experimental
evidence has supported its ability to alter behaviour 
in controlled laboratory settings, but has not yet shown
a superiority to other approaches in controlled trials
[1].
■ Psychopharmacological treatment
There is a substantial evidence base for the effect of
methylphenidate over treatment periods up to a year
and in doses up to 60 mg daily. Numerous placebo-con-
trolled randomised control trials confirm the substan-
tial short-term benefit [131, for meta-analysis see 72, for
systematic reviews, see 141, 89]. Stimulants markedly
and rapidly reduce the overt clinical manifestations of
restlessness, inattentiveness and impulsiveness; they im-
prove the quality of social interactions, decrease aggres-
sion and increase compliance.
Two other stimulants, dexamfetamine and pemoline,
have been shown to be more effective than placebo in a
smaller number of short-term trials, conducted some
years ago. Methylphenidate and dexamfetamine are
licensed for children in most European countries.Where
they are not licensed, it is sometimes in the context of
legal frameworks to prevent drug abuse,but can have the
effect of leading to the use of more toxic drugs to con-
trol hyperactivity.
Stimulant medications also have limitations: They
are not an acceptable treatment option for some chil-
dren and families. Many families believe that their
child’s problems reside in the context of key relation-
ships or in the child’s school. Lack of adherence limits
the effectiveness of medication, as it does with all med-
ical treatments.Although generally safe, stimulant med-
ication does have side-effects in a proportion of recipi-
ents that, in some cases, result in the termination of
treatment (see below).
Superiority to placebo in random-allocation, double-
blind trials of varying methodology has also been re-
ported for atomoxetine and clonidine; for tricyclic anti-
depressants such as imipramine and desipramine; and
for neuroleptic antidopaminergic drugs (thioridazine,
haloperidol).
■ Indications
Medication should be considered when (i) the patient
meets the DSM-IV criteria for the AD/HD syndrome
and (ii) psychological treatments are insufficient alone
or the criteria for primary use of medication are met
(see ‘Integration of approaches’).
A single drug should be initiated first. If efficacy or
tolerability of the given agent should turn out to be un-
satisfactory, an alternative monotherapy should usually
be initiated, before combined psychopharmacological
therapy is introduced (see below).
Details of prescription are generally not based on rig-
orous evidence, but our consensus recommendation is
that initial medication should be as a trial, and
methylphenidate is usually the first choice. The treat-
ment should be discussed and explained before it is
started; and in the early stages of treatment the family
(and preferably the teacher) will need a quick and ready
access to the prescriber to report progress and any ad-
verse effects.
The effect lasts only for a few hours: Three daily doses
are recommended,but practical considerations may dic-
tate a twice daily regime. The dosage should begin at a
low level (0.2 mg per kilogram per dose) and be in-
creased in the light of response. The amount should be
increased until either a good result is achieved, or ad-
verse effects appear, or a ceiling of 0.7 mg per kilogram
per dose is achieved – whichever comes first.
Longer-acting preparations of methylphenidate may
also be used from the start of therapy. They are some-
what more expensive, and not available in all countries,
but carry many advantages if the effect is long enough to
make additional doses at school unnecessary. This
makes the treatment more private, avoids stigma at
school, and therefore improves compliance. From the
school’s point of view, it is hard to overstate the advan-
tage that comes if dispensing a controlled medication is
no longer on the list of school responsibilities. OROS-
methylphenidate (Concerta) is the only such prepara-
tion to be widely available outside North America at pre-
sent; an initial dose of 18 mg daily can be increased at
intervals of 1 week up to 54 mg daily. If it is not effective,
then immediate-release methylphenidate should be
tried in repeated doses, titrated according to the re-
sponse.
Careful and detailed titration of dosage and timing is
likely to improve response. The large North American
trial of multimodal treatments [105, 106 described be-
low] compared children with AD/HD who had been ran-
domly assigned to routine community treatment (usu-
ally including medication) or to carefully crafted
medication, in which varying doses of methylphenidate
were given, monitored daily for a month, and the best
dose for the child chosen for continuing therapy. This is
an expensive process, so it seems logical to reserve en-
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hanced monitoring for those who have not responded to
routine therapy.
■ Adverse effects of stimulant medication
Sleeplessness is a frequent presenting problem. It is clin-
ically important to distinguish those children whose in-
somnia is an untoward effect of the drug from those
children whose insomnia may be due to the recurrence
– or worsening – of behavioural difficulties as the med-
ication effect subsides.For the first group of children,re-
ducing the last dose of the day may be sufficient. For the
latter group, an evening dose may be helpful [58].
Nervousness, dysphoria, and appetite reduction are
most common at the beginning of treatment. They may
be controlled by dose reduction. Uncommon problems
include skin rash, nausea, dizziness, headache, weight
loss,and changes in blood pressure.Motor tics and man-
nerisms may emerge at any stage of treatment; if they
do, then judgement is needed as to whether they are so
severe that the treatment must be stopped, reduced or
replaced with another medicine. Overdose produces
many harmful effects, including delirium, confusion,
tremors, sweating, vomiting and muscle twitching.
Growth can be affected. If there are indications of
growth retardation, drug holidays (e. g. during the sum-
mer vacation) are recommended [119, 158].
Emotionally unstable adults, or those with a history
of substance abuse, may increase a prescribed dose on
their own initiative. Chronic abuse of high-dose
methylphenidate can lead to tolerance and psychic de-
pendence with varying degrees of abnormal behaviour.
Frank psychotic episodes may occur, especially in re-
sponse to parenteral abuse.
Epilepsy is not necessarily a contraindication. It is
said that methylphenidate may lower the convulsive
threshold in animals, but experience suggests that
methylphenidate can be safe and effective in most chil-
dren and adolescents with coexisting seizure disorders
and AD/HD [61, 68, 82] – at least if the epilepsy is well
controlled. Less is known about those with poorly con-
trolled epilepsy, so frequency of seizures should be care-
fully monitored, and if their frequency increases, or
seizures develop de novo, then methylphenidate should
be stopped. Dexamfetamine is then a good substitute.
■ Precautions and monitoring
We regard all the stimulants as contraindicated in: schiz-
ophrenia,hyperthyroidism,cardiac arrhythmias,angina
pectoris, and glaucoma; and, of course, when the drug
has previously caused hypersensitivity. Caution is
needed in the presence of hypertension, depression, tics
(or a family history of Tourette’s syndrome), pervasive
developmental disorders, severe mental retardation, or a
history of drug dependence or alcoholism.
Monitoring should include recording blood pressure
and pulse (at each adjustment of dose, then every 6
months); height, weight and appetite with maintenance
of a growth chart (6 monthly); tics, depression, irritabil-
ity, lack of spontaneity, withdrawal, and excessive perse-
veration (at every visit). Manufacturers recommend pe-
riodic blood tests to detect any haematological
abnormality, but we are aware of no evidence for this
practice and think that the remote chance of benefit is
usually outweighed by the unpleasantness for the child.
■ Abuse potential of psychostimulants
Much has been made in the media about the similarities
between methylphenidate and cocaine. Both drugs work
by blocking the dopamine transporter and indeed
methylphenidate is more effective than cocaine in this
respect [178]. Detailed studies, however, have demon-
strated important pharmacokinetic and pharmacody-
namic differences between the two drugs. As a result of
these differences methylphenidate, when taken in clini-
cal doses and within a clinical context, appears to be as-
sociated with a much lower abuse potential than cocaine
[177]. There is some evidence (e. g. from police seizures)
to suggest that small quantities of methylphenidate are
diverted towards illicit use, but rates of methylphenidate
misuse seem to be low and those who do choose to abuse
it do so mainly by intravenous injection.
Arguments have been put forward suggesting that
exposure to stimulant medications early in life may lead
to the development of sensitisation and cross-sensitisa-
tion which may render an individual more likely to
abuse drugs in later life [122]. The findings from animal
studies regarding the development of sensitisation to
methylphenidate are contradictory and there have been
no well-designed studies to address these issues in hu-
man subjects [121]. It is therefore not possible to answer
the question,“does early exposure to stimulant medica-
tion lead to sensitisation to stimulant or other medica-
tions in later life?” with any degree of certainty. The
available clinical data suggest that, whether or not sensi-
tisation occurs, the net effect of treating children and
young people with AD/HD with stimulant medication is
to protect against, rather than lead to, later substance
misuse. A meta-analysis of the available literature re-
ported that those treated with stimulants were protected
against the development of substance misuse problems
by a factor of almost two (Odds Ratio, 1.9), compared
with those whose AD/HD was not treated with stimulant
medication [184]. Possible mechanisms for this protec-
tive effect include a reduction in AD/HD symptoms es-
pecially impulsive behaviour, a reduction in conduct
disorder and later anti-social personality disorder, im-
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proved academic performance and career, or improved
peer and family relationships.
■ Other drugs
Dexamfetamine is also a useful stimulant.The effects are
clinically similar to those of methylphenidate; but some
patients who do not benefit from methylphenidate re-
spond to dexamfetamine, and vice versa [20]. The dose
is half that of methylphenidate.
Pemoline is a longer-acting stimulant, usually con-
sidered to have its main actions on the inhibition of
dopamine reuptake. For children over 6 years, the start-
ing dose is 2 tablets (of 18.5 or 2 mg) daily; it should be
increased by one daily tablet each week; the usual main-
tenance level is 4 to 6 tablets daily (usually given in two
divided doses). Clinical benefit may not be evident un-
til the third or fourth week of therapy. It can induce an
elevation of hepatic enzyme levels that is usually minor
and can easily be managed by discontinuing the drug.
There have, however, been at least two published reports
of death due to liver failure [15, 108]. Because of this,
the drug is not on the market in most European coun-
tries.
There are different non-stimulant drugs in use to
treat ADHD [8]. Replicated evidence was shown from
multi-centre randomised controlled trials for the effi-
cacy of atomoxetine in AD/HD [96]. Atomoxetine is a
specific potent norepinephrine reuptake inhibitor simi-
lar in structure to fluoxetine.Data about school and cog-
nitive effects so far are limited.Atomoxetine has been li-
censed in the USA but no license has been given yet in
Europe – though it is under consideration.
Other unlicensed treatments include tricyclic antide-
pressants, antihypertensives and bupropion; the evi-
dence base derives from small-scale trials with method-
ology that reviewers have criticised [72]. Their use is
essentially in specialist practice where their hazards are
understood and monitored.
Desipramine and imipramine are tricyclic antide-
pressants, with an antihyperactivity action that is prob-
ably due to their ability to inhibit norepinephrine up-
take. These medications are usually considered when
methylphenidate or another stimulant may make tics
worse, or has been ineffective, or has exacerbated emo-
tional disturbance. In AD/HD patients with tics, de-
sipramine is more effective than clonidine on the
symptoms of AD/HD [146]. Dose should be built up
step-wise, over two weeks, to a total of 2.5 mg/kg/day,
divided into two or more doses (at morning and
evening). Effect evaluation should come after two weeks
on a stable dosage.
Adverse effects of desipramine include drowsiness,
sleep disturbances, anxiety, headache, dizziness, dry
mouth, sweating, constipation, blurred vision, hypoten-
sion, tachycardia, weight gain, nausea and allergic skin
reactions. The most worrying hazard is on the cardio-
vascular system with an increase in tachycardias and a
possible deterioration of the ECG even two years after
the start of the treatment. Most treated children show 
no ECG change, but a few cases of sudden death, pre-
sumably due to cardiac arrhythmia, have been reported
in children. The drug has therefore been withdrawn in
some countries. Desipramine, like other tricyclics,
should be seen as having a cardiotoxic potential that
varies greatly between children [180]. When they are
prescribed, then children should have pulse, blood pres-
sure and ECG monitoring at baseline, after each dose in-
crease and then every 3 months. Plasma levels should be
monitored if anything more than a small dose is given.
Female patients seem to reach higher blood levels with
the same weight-adjusted dose than male patients, and
also show more side-effects [59].
Imipramine may be used instead of desipramine.
Children over the age of 6 years should start with 10 mg
daily, increase over a period of 10 days to 20 mg (up to
the age of 8 years), to 20–50 mg (up to the age of 14 years)
and to 50–80 mg (for patients over 14 years). Adults
should start with 25 mg and be raised gradually to a
maximum of 150 mg daily. For maintenance therapy in
adults, 50–150 mg daily is the usual dose range.
Clonidine and guanfacine are alpha-2-noradrenergic
drugs which have a presynaptic action to reduce the re-
lease of noradrenaline. They may be used when
methylphenidate, or another stimulant, and tricyclics
have been ineffective or contraindicated. The dosage of
clonidine, which should be built up gradually over 2 to 4
weeks, is usually 3–5 µg/kg/day, divided into two doses
(at breakfast and bedtime). Effect evaluation is after six
weeks on the full dosage. The most common adverse ef-
fects are sedation, drowsiness, and depression. Ortho-
static hypotension and cardiac arrhythmias are rare but
potentially serious; thus the therapist should monitor
blood pressure, pulse and electrocardiogram. Con-
traindications include cardiac arrhythmias (especially
sick sinus syndrome) and major depression; special pre-
cautions are needed in impaired renal function. The
medication should not be stopped abruptly because of
the risk of rebound hypertension and tics.
Neuroleptics such as risperidone appear to be less
helpful for hyperactive behaviour than stimulants, and
they do not reliably produce cognitive improvement.
They can be helpful in low daily doses (e. g. risperidone
0.5 to 1.5 mg/day, usually in two doses) when there is co-
morbid pervasive developmental disorder or when se-
vere aggression or affective instability – especially in
those with intellectual disability – requires drug therapy
[3]. Potential side-effects that require careful monitor-
ing are weight gain and sedation. The risks usually ex-
ceed their possible usefulness in the treatment of un-
complicated AD/HD and would require careful
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consideration before use. Behavioural therapy remains
the best evaluated treatment in severely challenging be-
haviour problems.
■ Effect evaluation
The items of the Attention Problems and Hyperactivity
factor scores of the CBCL, Conners scales and TRF are
useful ways of measuring behaviour change [80] and are
appropriate for monitoring other drug treatments as
well. In addition, before the start of medication parents
and teachers may be asked to select (for example) three
problem behaviours as targets for the medication effects
and to give a mark for each target [2, Checklist of Target
Problems, see Appendix]. After one week on a stable
dosage both the parents and the teacher are asked to
mark again. The effect of the treatment is only consid-
ered favourable if the improvement is considerable, and
there are no persistent adverse effects. Comparison with
a placebo is a powerful way of assessing effect, but it is
not needed routinely [see 75].
■ Duration of treatment
Longer term evidence of efficacy is hard to obtain, but
trials are in progress [52]: methylphenidate is still more
effective than placebo over periods in excess of a year. In
practice, length of treatment is not fixed in advance, and
may well need to be for some years. It should be discon-
tinued periodically (e. g.once a year) to assess the child’s
condition and continuing need for therapy. A common
mistake is to stop treatment prematurely.
Treatment will sometimes need to continue into adult
life. Some randomised controlled studies have showed
that adults are sometimes helped by methylphenidate
[62, 179, 159]. Adult patients are variable in their dosage
requirement, and up to 1.0 mg/kg/dose has been used
[159]; or even 2 mg/kg daily [182]. Tricyclic antidepres-
sants may be considered for nonresponders or adults
with concurrent psychiatric disorders.
■ Combinations of drugs
Stimulants should not be administered with
monoamine oxidase inhibitors (MAOIs) or until a pe-
riod of at least 14 days has elapsed since MAOIs were in-
gested, to avoid possible hypertensive crises [58].
The blood level of tricyclics is unpredictably in-
creased if methylphenidate is given simultaneously, so
the combination should be given, if at all, only with close
monitoring of blood level and ECG. The metabolism of
coumarin anticoagulants, some anticonvulsants (phe-
nobarbitone, phenytoin, primidone) and phenylbuta-
zone may also be inhibited by methylphenidate, requir-
ing dose reductions.
Clonidine can produce intraventricular conduction
delay and T wave abnormalities, so careful ECG-moni-
toring is recommended if clonidine is used with other
drugs affecting the cardiovascular system.
Tricyclic antidepressants in combination with neu-
roleptics (especially pimozide) can result in an intra-
ventricular conduction delay. The combination is best
avoided unless there are very strong clinical reasons for
it.
■ Nutritional approaches
Dietary treatment has a bad name, largely because of
some widely promoted claims that dietary salicylates,
food colourings and preservatives were the main cause
of hyperactivity [48]. These views are now known to be
false [95]. Many other diets without the support of
clinical trials are promoted from time to time. Popular
recent examples include the restriction of sugar, the ad-
ministration of evening primrose oil, and hyposensiti-
sation to defined allergens; the limited trial evidence in-
dicates that they are of little value and should not be
prescribed. Fish oils have been introduced more re-
cently, but there is not enough evidence to recommend
one way or the other.
There is limited trial evidence for the value of elimi-
nation diets that seek to exclude foods – different for
each child – to which intolerance exists [27, 41, 78, 140].
Cows’ milk, wheat flour, citrus fruits and food dyes are
among the most commonly incriminated foods. On the
other hand, a community survey has indicated that the
majority of children, whose parents believe them to be
food sensitive, are not [189]. The resolution seems to be
that at least a few children with hyperactive behaviour
are reacting badly to food, but that an elimination diet
will help only a minority. The diets are troublesome to
apply, and they are often rejected by older children.
We have to conclude that there is not yet enough sci-
entific evidence to establish guidelines for dietary treat-
ment. More research is needed.A food diary approach is
a non-intrusive way of establishing whether there is a
link between behaviour and food intake; if there is, then
a mental health professional can help to monitor behav-
iour over several weeks while a suitable dietary regime
for the individual child is worked out.A dietician should
be consulted before any strict elimination approach
(such as the “few foods diet”) is attempted.
■ Integration of approaches
European clinicians are often presented with the choice
between psychological treatment and medication as the
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first specific therapy after diagnosis, education, advice
and support. One large-scale trial in the USA – the MTA
study – has focused on the comparison of the two kinds
of treatment [105, 106]. Children were randomly allo-
cated either to careful medication management, to in-
tensive behaviourally oriented psychosocial therapy, to
a combination of the two, or to a simple referral back to
community agencies (which usually resulted in medica-
tion). The main conclusions were that careful medica-
tion is more powerful than behaviour treatment, and
considerably more effective than routine medication in
the community. There were many advantages in adding
medication to behaviour therapy; but relatively few to
adding behaviour therapy to medication. The superior-
ity of careful medication to behaviour therapy was all
the more striking in that the behaviour therapy provi-
sion was more intensive and prolonged than could be
achieved by a community service. Combined therapy
had some benefits: for example, the control of aggressive
behaviour at home, improving the overall sense of satis-
faction of parents and achieving “normalisation” (the
reduction of problems to a level where none was rated as
more than minor). These improvements are real, but
would probably not justify the very high costs of the full
treatment package in this research-based form.
It does not follow that medication is always the first
choice in treatment. Though behavioural therapy may
be less effective, it is still helpful for many children and
multimodal behavioural interventions with parent
training, interventions in school and cognitive behav-
iour therapy of the child have been shown to be effective
in a substantial proportion of patients [162, 36]. The
costs of a short course of parent training are compara-
ble to those of medication; the outcome may be some-
what less favourable in terms of symptom reduction, but
has the advantage of carrying very little physical hazard.
A reanalysis of the MTA study has assessed whether
its conclusions apply to hyperkinetic disorder (Santosh
et al., personal communication). The answer is that they
do: the superiority of medication to behaviour therapy
is greater in hyperkinetic disorder than in other types of
AD/HD, and the effects of behaviour therapy appear to
be less. Most children whose problems are severe
enough to receive a diagnosis of hyperkinetic disorder
will need medication. Family attitudes should of course
be respected; but if a trial of psychological treatment has
not produced substantial improvement within a few
weeks, then medication should be advised.
For children at lesser degrees of severity – those who
show AD/HD but not hyperkinetic disorder – the choice
of initial therapy is more evenly balanced. In these
milder cases there are options about which treatment to
start with. Decisions will depend on the analysis of the
individual child, the strengths and weaknesses of their
school and classroom environment, the severity of dis-
turbance of peer relationships, and the preferences of
the families. It is quite reasonable to start with either
therapy, in the knowledge that one will proceed to the
other should the response be suboptimal.
Children who show attention deficit without hyper-
activity may also present suitable targets for stimulant
medication.Research evidence is rather scanty but tends
to favour the idea that stimulants are useful, often in
lower doses than are required for the control of overac-
tive and impulsive behaviour. Certainly inattentiveness
is improved in children with mixed types of AD/HD, and
indeed poor scores on attention tests predict a good re-
sponse to methylphenidate within mixed groups of chil-
dren with AD/HD. Care needs to be taken in the inatten-
tive subgroup: first, that the degree of impairment is
sufficient to justify the hazards of medication; and, sec-
ond, that the inattentiveness is indeed a specific problem
and not just an expected part of a more global pattern of
mental retardation.
The need to have a second line of therapy for some
children should particularly be stressed when behav-
iour therapy has been chosen as the first option. It is not
rational to prolong any kind of psychological therapy in
the face of suboptimal improvements and there should
not be undue delay in proceeding to medication for
those children whose behaviour is still holding back
their development in school, and their social relation-
ships. Fig. 1 illustrates a treatment algorithm that
embodies these principles,while Fig. 2 illustrates a treat-
ment algorithm for ADHD refractory to methylpheni-
date.
Additional problems are often present, and if so they
may need treatment whether or not the core symptoms
of hyperactivity have been reduced by specific treat-
ments. Training of social competence is often needed. It
may help children to make and keep relationships, solve
interpersonal problems and provide substitutes for ag-
gressive behaviour to peers. Trials have not yet given
clear evidence of the value of any one technique. Group
therapy and behavioural instruction in naturalistic set-
tings should be considered. Individual psychotherapy
may need to be undertaken for poor self-esteem. Again,
there is a dearth of experimental evidence; many clini-
cians favour short-term and cognitively based psy-
chotherapies. Remedial teaching of academic skills may
be needed for co-existent learning disorders. The cur-
riculum may need to be modified, and individual atten-
tion from a teaching aide provided. Family support may
need to go beyond the provision of advice, guidance and
treatment and include the financial help appropriate for
a disabled child and the provision of short periods of
respite care.
Comorbidity with other psychiatric disorders is com-
mon, and poses some problems for the therapist that re-
search has not yet answered. Treatment in these circum-
stances is guided more by experience than trials, and
more trials should be undertaken.
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When AD/HD is comorbid with a conduct disorder
then we recommend treating the AD/HD first, as above,
since the conduct disorder is often secondary. Parent
management training and cognitive behavioural ther-
apy can then be provided for the conduct problems, and
are often needed [69].
AD/HD with comorbid anxiety disorders is not ne-
cessarily refractory to stimulants and anxiety is not a
contraindication. However, a further search for psycho-
logical stresses on the child is in order, and if they can-
not be simply alleviated then psychological treatment
may have more to offer than repeated drug trials.
Comorbid tics often present problems because they
may be worsened by stimulants. This is not inevitable,
and stimulants are sometimes useful even for the hyper-
activity seen in Tourette’s syndrome. However, there is
some evidence that in a few children with AD/HD, tics
may be triggered or exacerbated by stimulants. If a
dosage reduction of stimulants does not lead to an im-
provement of the tics, or if the presentation of tics plays
an important role concerning psychosocial impairment
of the child, the parallel use of stimulants and tic-reduc-
ing drugs (e. g. tiapride, risperidone, pimozide, cloni-
dine) seems to be indicated. Coexisting tics and hyper-
kinetic symptoms can be treated with tiapride only, or a
noradrenergic agent, if hyperkinetic symptoms are
mild. Behavioural therapy may be added for tics and ob-
sessive symptoms. Careful monitoring is needed and a
specialist centre should usually be involved.
When AD/HD is comorbid with a pervasive develop-
mental disorder, then again specialist advice should be
sought. There is little trial evidence, but we suggest that
even in autism it may be worth a trial of medication for
the symptoms of AD/HD. Methylphenidate itself is often
the most helpful; clonidine, atomoxetine, and even
risperidone may have their place. Behavioural therapy,
targeting the AD/HD symptoms, is widely applicable.
For treating individuals with AD/HD and an estab-
lished comorbid substance misuse disorder, there is lit-
tle research evidence to guide clinicians. Treatment
plans should address both disorders and should include
psychosocial interventions aimed at reducing substance
misuse and relapse prevention. There are indications
that effective treatment of core AD/HD symptoms may
enhance effective treatment of substance misuse [120].
Pharmacological therapies for AD/HD should be started
Fig. 1 Initial treatment of children with activity/attention problems
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with caution and under close supervision. Medications
should be given by a supervising adult and securely
stored.Whilst immediate release stimulant preparations
are likely to be effective they are potentially more abu-
sable than the extended release preparations. OROS
methylphenidate, in particular, is difficult to extract into
a form that can be abused.Where stimulant treatment is
considered inappropriate non-stimulants may be con-
sidered. There are indications that bupropion may be an
effective treatment for this group [87, 120] but further
controlled studies are required. Where available, atom-
oxetine is likely to be an attractive effective treatment
option for this group.
■ Diagnosis and management in pre-school
In the USA,but not for the most part in Europe, there has
been a dramatic recent increase in the number of chil-
dren below the age of five who have been treated for
AD/HD The literature on this age group remains limited
and the recommendations set out here remain tentative
[153].
Recent evidence supports the view that pre-school
AD/HD, while taking a somewhat different form from
school-aged AD/HD, shares many elements with it and
has generally similar levels of validity and utility. Symp-
toms of preschool inattentiveness, impulsiveness and
overactivity cluster together [156] and this cluster has
largely equivalent associations to those seen with
school-aged children in terms of intellectual (e. g. pre-
academic skills and developmental delay), behavioural
(e. g. ODD and Developmental Co-ordination Disorder)
and neuropsychological characteristics (both executive
deficits and delay aversion) [39, 50, 154, 160, 181]. There
also appear to be continuities between pre-school symp-
toms and later AD/HD and associated impairments such
that pre-school AD/HD is likely to represent a signifi-
cant barrier to school readiness [93].
Nevertheless, case identification remains uncertain.
Future research should introduce new and more age-ap-
propriate diagnostic items, definitions and thresholds.
Age-specific criteria for impairment that place special
emphasis on non-parental report will be needed, and
ways of distinguishing a transitory developmental hia-
tus from early onset chronic problems will be important.
Management should be correspondingly cautious,
especially with regard to drugs. Most of the small num-
ber of studies using stimulants with pre-school children
report similar levels of short-term symptom control to
those with school-aged children.Short-term side-effects
may be more marked amongst pre-schoolers and these
Fig. 2 Treatment for ADHD refractory to methylphenidate
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may be especially pronounced in children with learning
disabilities [64, 104]. The issue of long-term side-effects
has not been addressed clinically, but animal models
suggest that early administration of methylphenidate
has chronic effects on neuro-transmitters in the pre-pu-
bertal rat brain [103]. There is an urgent need for sys-
tematic studies.
Psycho-social approaches, by contrast, may be even
more valuable in the pre-school than the school years.
Two studies have demonstrated that parent training in
particular seems to be effective in reducing both core
symptoms of AD/HD and associated oppositional be-
haviour [19, 115]. These studies give credence to the
view that effective early intervention is possible if chil-
dren can be treated in pre-school before AD/HD behav-
iours become compounded with factors associated with
school failure (e. g. low self esteem; peer relationship
problems etc.), hardening of adult attitudes and the de-
terioration of adult-child interactions. At present there
is little evidence that the benefits of PT delivered in the
home generalise to nursery-school settings or that the
benefits of these approaches are sustained over the
longer term.
■ Delivery of treatments
Most specific treatments will be given in secondary care.
A mental health or behavioural paediatric service will
probably need to make special arrangements for the
children who receive stimulant medication.The need for
technically knowledgeable follow-up over long periods
is well met by a specialist clinic.
Secondary care should also be able to provide psy-
chological therapy and educational advice and liaison.
This will entail building up good working relationships
with local agencies. For school interventions, the collab-
oration of the teacher is prerequisite. Furthermore, suc-
cessful delivery of behavioural interventions in the
classroom will probably need the school system to sup-
port it, not just the individual teacher. Long-term liaison
with schools can achieve a great deal, both in case-find-
ing and in the development of a whole school response.
One member of the staff, for example, may become a re-
source for training aides and other teachers.
Home interventions, too, require understanding and
cooperation from parents and children. This can be im-
paired by other problems straining family resources – fi-
nancial, mental health or disturbed relationships. Fam-
ily meetings with a therapist can be an excellent way of
mobilising problem-solving skills. The therapist should
remember that most families have a long experience of
being blamed, and blaming themselves, for behaviour
problems of their children. Guilt and shame may need to
be lessened before focussed therapies are feasible. Many
parents are exquisitely sensitive to therapist attitudes
that can be construed as attributing blame, and need
time to build trust.
Complex or refractory cases, often those with severe
comorbid problems or failures of care, will need referral
to a regional specialist centre that can provide intensive
monitoring, detailed psychological and neurological as-
sessment, a range of psychological therapies and exper-
tise in the use of drugs. Day- or in-patient treatment fa-
cilities are needed for some cases, for example to allow
close monitoring or more intensive work with families.
A specialist centre should be linked to a university de-
partment and in current touch with the rapidly advanc-
ing body of research.
■ The role of support groups
Support groups in many European countries have ambi-
tious goals, both for the support of individual sufferers
and their families, and in public campaigning. At the
level of assistance to individuals, they can help greatly in
disseminating information about the disorders, devel-
oping advocacy work, and providing groups for parents
or teenagers or adult sufferers. It is very helpful if such
groups can maintain a comprehensive approach. Their
credibility, and avoidance of factionalism, are important
in persuading society of the importance of recognising
and treating the hyperkinetic disorders of childhood.
Appendix
■ Recommended assessment instruments
Questionnaires
Child Behavior Checklist (CBCL):
Achenbach TM (1991a) Manual for the Child Behavior Checklist/4–18
and 1991 Profile. Burlington, University of Vermont, Department of
Psychiatry
Child Communication Checklist
ADHD, Dyslexia, High Functioning Autism
Purvis and Tannock (1997) studied whether the language difficulties
of ADHD children could be accounted for by difficulties in the organ-
ization and monitoring of their reconstruction of a story, suggesting
a pragmatic problem in ADHD children.Dyslexic children had no dif-
ficulty in organization or monitoring of their reconstruction but had
semantic and receptive language difficulties. ADHD children comor-
bid for dyslexia had difficulties with both classes of language prob-
lems.Geurts et al. (2004) compared HFA and ADHD children on rated
language proficiency with the Child Communication Checklist
(Bishop 1998). Children with HFA could be reasonably differentiated
from children with ADHD in terms of their language deficits. Chil-
dren with HFA showed more profound language deficits compared to
children with ADHD. Luteijn et al. (2000) showed that children with
autism have the most profound communication deficits (including
pragmatics) compared to other clinical groups, including children
with ADHD.
Bishop DVM (1998) Development of the children’s communica-
tion checklist (CCC): a method for assessing qualitative aspects of
communicative impairment in children. J Child Psychol Psychiatry
39:879–891
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Bishop DVM, Baird G (2001) Parent and teacher report of prag-
matic aspects of communication: Use of the Children’s Communica-
tion Checklist in a clinical setting. Developmental Med Child Neurol
43:809–818
Geurts HM, Verté S, Oosterlaan J, Roeyers H, Hartman CA., Mul-
der EJ, van Berckelaer-Onnes, Sergeant JA (2004) Can the Children’s
Communication Checklist Differentiate between Children with
Autism, Children with ADHD, and Normal Controls?
Conners’ Parent Rating Scale (CPRS)
Conners CK (1989) Conners’ Rating Scales Manual. New York, Multi-
Health Systems
Conners’ Teacher Rating Scale (CTRS)
Conners CK (1989) Conners’ Rating Scales Manual. New York, Multi-
Health Systems
Disruptive Behavior Disorder Checklist
Pelham W, Gnagy EM, Greenslade KE, Milich R (1992) Teacher ratings
of DSM-III-R symptoms for the disruptive behavior disorders. Jour-
nal of the American Academy of Child and Adolescent Psychiatry
31:210–218
Home Situations Questionnaire
Barkley RA (1991) Attention-deficit hyperactivity disorder. A clinical
workbook. New York, Guilford Press
Iowa Conners Teacher Rating Scale
Loney J, Milich R (1982) Advances in Developmental and Behavioral
Pediatrics 3:113–147
Revised Behavior Problem Checklist (RBPC)
Quay HC (1983) A dimensional approach to behavior disorder: The
Revised Behavior Problem Checklist. School Psychol Rev 12:244–249
Rutter Scales
Rutter M,Tizard J,Whitmore K (eds) (1970) Education,health and be-
haviour. London, Longmans Green
School Situations Questionnaire (SSQ)
Barkley RA (1991) Attention-deficit hyperactivity disorder. A clinical
workbook. New York, Guilford Press
SNAP-IV-Rating Scale
Swanson J (1992) School-based assessments and interventions for
ADD students. Irvine, K. C. Publishing
Strength and Difficulties Questionnaire (SDQ) for parents, teachers
and youth
Overview in Rothenberger A, Woerner W (eds) (2004) Strenghts and
Difficulties Questionnare (SDQ) – Evaluation and Application. Eur
Child Adolesc Psychiatry (suppl)
Internet: sdqinfo.com
Teacher’s Report Form of the Child Behavior Checklist (TRF)
Achenbach TM (1991b) Manual for the Teacher’s Report Form and
1991 Profile. Burlington: University of Vermont, Department of Psy-
chiatry
Youth Self-Report (YSR)
Achenbach TM (1991c) Manual for the Youth Self-Report and 1991
Profile. Burlington: University of Vermont, Department of Psychiatry
Interviews
Diagnostic Interview Schedule for Children – Child & Parent Inter-
views
Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME (2000)
NIMH Diagnostic Interview Schedule for Children version IV (NIMH
DISC-IV): Description, differences from previous versions, and relia-
bility of some common diagnoses. J Am Acad Child Adolesc Psychia-
try 39: 28–38
Parental Account of Children’s Symptoms (PACS)
Taylor EA, Schachar R, Thorley G, Wieselberg M (1986) Conduct dis-
order and hyperactivity: I. Separation of hyperactivity and antisocial
conduct in British child psychiatric patients. Br J Psychiatry 149:
760–767
Neuropsychological assessment
Tests of Executive Functioning
Sergeant JA, Geurts H, Oosterlaan J (2002) How specific is a deficit of
executive functioning for Attention-Deficit/Hyperactivity Disorder?
Behav Brain Res 130:3–28
Continuous performance
The Continuous Performance Test (CPT) has been used in a vast
number of studies in both ADHD and autism, as well as other child-
hood psychopathological conditions. Poorer vigilance (d’) has been
found in virtually every child disorder compared with controls (see
for meta-analysis Losier, McGrath & Klein, 1996). The effect size for
the ADHD – control comparison differed slightly for omission errors
(E. S. = 0.67) and commission errors (0.73), which are moderate to
good effects.
Inhibition
Stop task: a useful task in discriminating children with ADHD from
controls (Oosterlaan, Logan & Sergeant, 1998).
Stroop: The Stroop test and its differential diagnostic significance
was reviewed by Sergeant, Geurts & Oosterlaan (2002). This head-
count indicated that a number of studies (ten) had reported deficits
in ADHD and in the related-disorders ODD/CD.An unpulished meta-
analysis has subsequently shown that the difference between ADHD
and control children is, at best, a weak one (van Mourik et al. under
review).
Planning
Planning is the ability to ‘look ahead’, to construct a plan, and to eval-
uate and monitor execution of a plan. The attainment of a future goal
is reached through a sequence of intermediate steps,which not always
directly lead to the future goal. Sergeant et al. (2002) tabulated five
studies, which differentiated ADHD from controls and two studies
that reported no difference.A recent study compared HFA and ADHD
children and found that the execution time of HFA was longer than
both ADHD and control children (Geurts et al. 2003). There is some
support for the view that HFAs perform poorer than ADHD children
in a planning task.
Fluency
In fluency tasks the participant is required to generate sets of appro-
priate responses to a given set of stimulus conditions. The tasks differ
in the responses a subject is required to give. The main conditions are
letters, categories, and designs. Cognitive processes involved in flu-
ency include processing speed, size of the vocabulary, semantic mem-
ory, working memory, inhibition, and set maintenance.
Six studies contrasted ADHD children with controls on letter flu-
ency and found poorer performance in ADHD compared with con-
trols (see Sergeant et al. 2002).
Set Shifting
WCST: The Wisconsin Card Sorting Test (WCST) is used traditionally
as a test to tap set shifting. The WCST differentiates between ADHD
children and controls (see Sergeant et al. 2002). The WCST differenti-
ated in 11 studies children with HFA from controls but two did not.
Perseveration errors in the WCST have been found to differentiate
HFA from ADHD children (Geurts et al. 2003). The WCST can diffe-
rentiate between ADHD and controls and HFA from ADHD children
(Verté et al. under review).
Working memory
Working memory tasks tap several processes: maintenance and ma-
nipulation of working memory, inhibitory control, the ability to gen-
erate and perform a sequence of responses, phonological and visuo-
spatial abilities and requires an episodic buffer. The Corsi, often
considered a working memory task, differentiates High Function
Autism (HFA) from controls but not ADHD from controls; the com-
parison HFA – ADHD did not reach significance (Geurts et al. 2003).
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Non-executive functioning tests/tasks
Benton
Geurts et al. (2003) found no difference between HFA and ADHD chil-
dren.
Delay Aversion
Tasks that investigate delay aversion may be useful in the assessment
of ADHD children (Sonuga-Barke, Taylor, Sembi, & Smith, 1992).
There is considerable interest in this task since it has been shown to
differentiate ADHD from controls but also to do so independently of
inhibition deficits (Solanto et al. 2001).
Timing
ADHD children have been demonstrated to have deficits in motor
timing, but not in their temporal perception (Rubia et al., 1999b). The
deficits observed in motor timing consisted of increased variability of
free tapping, synchronizing, and anticipating the motor response to
visual stimulation (Rubia et al., 1999b).
Rubia et al. (2003) found that a clinical ADHD group was impaired
in time perception,which was spared in a community group of ADHD
children. The persistent, but not the acute dose, of methylphenidate
reduced the variability of sensori-motor synchronization and antici-
pation, but had no effect on time perception. This study showed that
motor timing functions are impaired in both clinical and community
children with ADHD.The study showed the effectiveness of persistent
administration of methylphenidate on deficits in motor timing in
ADHD children.
Overview of tests
Continuous Performance Tests (CPT)
Conners CK (1985) The computerized Continuous Performance Test.
Psychopharmacology Bulletin 21:891–892
Conners CK (1994) The Conners’ Continuous Performance Test.
Toronto, Canada, Multi-Health Systems
Delayed Response Alternation
Weinberger DR, Berman KF, Gold J, Goldberg T (1994) In: Haith M,
Benson JB, Roberts RJ, Pennington BF (eds) The Development of Fu-
ture-oriented Processes. Chicago, University of Chicago Press
Matching Familiar Figures Test (MFFT)
Cairns E, Cammock T (1978) Development of a more reliable version
of the Matching Familiar Figures Test. Developmental Psychology 11:
244–248
Self-ordered Pointing
Petrides M, Milner B (1982) Neuropsychologia 20:249–262
Geurts HM, Verté S, Oosterlaan J, Roeyers R, Sergeant JA (2003) How
specific are executive functioning deficits in attention defcit hyperac-
tivity disorder and autism? J Child Psychol Psychiatry 43:1–19
Sequential Memory Test
Gorenstein EE, Mammato CA, Sandy JM (1989) Performance of inat-
tentive-overactive children on selected measures of prefrontal-type
function. Journal of Clinical Psychology 45:619–632
Stop Signal Task
Oosterlaan J, Logan GD, Sergeant JA (1998) Response inhibition in
AD/HD, CD, comorbid AD/HD+CD, anxious and control children: a
meta-analysis of studies with the stop task. J Child Psychol Psychiatry
39:411–426
Scheres A, Oosterlaan J, Swanson J, Morein-Zamir S, Meiran N, Schut
H, Vlasveld L, Sergeant JA (2003) The effect of methylphenidate on
three forms of response inhibition in boys with AD/HD. J Abn Child
Psychol 31:105–120
Stroop
Cohen JD, Servan-Schreiber D (1992) Psychol Rev 99:45–77
Mourik van R, Oosterlaan J, Sergeant JA (under review) The Stroop
Revisited: A Meta-Analysis of Interference Control in AD/HD
Timing
Rubia K, Taylor AM, Taylor E, Sergeant JA (1999) Synchronization, an-
ticipation, and consistency in motor timing of children with dimen-
sionally defined attention deficit hyperactivity behaviour. Perceptual
and Motor Skills 89:1237–1258
Rubia K, Noorlos J, Smith A, Gunning B, Sergeant J (2003) Motor tim-
ing deficits in community and clinical boys with hyperactive behav-
ior: The effect of methylphenidate on motor timing. J Abn Child Psy-
chol 31:301–313
Tower of Hanoi
Welsh MC, Pennington Ozonoff S, Rouse B, McCabe ERB (1990) Neu-
ropsychology of early-treated phenylketonuria: Specific executive
function deficits. Child Development 61:1697–1713
Tower of London
Shallice T (1982) Specific impairments of planning. Philosphical
Transactions, Royal Society London. Biology 298:199–209
Nigg JT, Blaskey LB, Huang-Pollock C, Rappley MD (2002) Neuropsy-
chological executive-functions and DSM-IV ADHD subtypes. Journal
of the American Academy of Child and Adolescent Psychiatry 41:
59–66
Trail Making, Part B
Reitan RM (1958) Validity of the Trail Making Test as an indicator of
organic brain damage. Perceptual and Motor Skills 8:271–276
Nigg JT, Blaskey LB, Huang-Pollock C, Rappley MD (2002) Neuropsy-
chological executive-functions and DSM-IV ADHD subtypes. J Am
Acad Child Adolesc Psychiatry 41:59–66
Wisconsin Card Sort Test (WCST)
Grant D, Berg E (1948) The Wisconsin Card Sort Test: Directions for
administration and scoring. Odessa, Psychological Assessment Re-
sources
WISC-R: Vocabulary,Arithmetic, Block Design and Picture Arrange-
ment
Groth-Marnat G (1990) Handbook of Psychological Assessment 2nd
edn. New York, Wiley
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